Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …

Monoclonal antibodies (mAbs) offer a treatment option for individuals with severe COVID-19
and are especially important in high-risk individuals where vaccination is not an option …

Summary The coronavirus disease 2019 (COVID-19) pandemic continues worldwide with
many variants arising, some of which are variants of concern (VOCs). A recent VOC, omicron …

Summary The SARS-CoV-2 Omicron variant with increased fitness is spreading rapidly
worldwide. Analysis of cryo-EM structures of the spike (S) from Omicron reveals amino acid …

The rapid spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.
1.1. 529 (Omicron) variant and its resistance to neutralization by vaccinee and convalescent …

Neutralizing antibodies can block infection, clear pathogens, and are essential to provide
long-term immunity. Since the onset of the pandemic, SARS-CoV-2 neutralizing antibodies …

The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus is continuously
evolving, and this poses a major threat to antibody therapies and currently authorized …

The vaccine and drug discovery responses to COVID-19 have worked far better than could
have been imagined. Yet by the end of 2021, more than 5 million people had died, and the …

Background The Delta and Omicron variants of SARS-CoV-2 are currently responsible for
breakthrough infections due to waning immunity. We report phase I/II trial results of UB-612 …

The coronavirus disease 2019 (COVID-19) pandemic is caused by the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), a recently emerged human coronavirus …